Opdivo replaces Nivolumab BMS for treatment of lung cancer

Opdivo (nivolumab) is now indicated in the treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy, in addition to its original indication in melanoma.

Nivolumab was originally launched for the treatment of NSCLC as Nivolumab BMS, but the manufacturer has now reconciled both indications under the Opdivo brand name. The two brands contain identical presentations of nivolumab and the same dosage regimen is used in both types of cancer.

The discontinuation of Nivolumab BMS will have no impact on patients with lung cancer already being prescribed nivolumab, other than a change in the brand name of their treatment. 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Asthma drug hailed as first non-hospital treatment for COVID-19

Asthma drug hailed as first non-hospital treatment for COVID-19

Inhaled budesonide is the first widely available, inexpensive...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Under-30s to be offered alternative to AstraZeneca COVID-19 vaccine after reports of rare blood clots